Cinnamon and Insulin Resistance — What Does the Meta-Analysis Show?

Insulin resistance — a state in which the body's cells respond more weakly to insulin, forcing the pancreas to produce ever larger amounts of it — is one of the most common targets of dietary and supplement interventions on the market. We cover it in more depth in our entry on insulin resistance, where we describe the mechanism and diagnostics. The popularity of this topic means that any substance promising improved insulin sensitivity — from berberine to apple cider vinegar — quickly attracts the attention of both researchers and supplement marketing.

Cinnamon is unusual within this group because it combines two things rarely found together: a presence in nearly every kitchen for thousands of years, and genuine scientific interest spanning several dozen clinical trials. It's exactly this combination — easy availability plus a growing body of publications — that makes cinnamon a regular fixture in blood-sugar guides, often accompanied by claims stronger than the available evidence actually supports.

Before we get to specific numbers, it's worth highlighting a distinction that easily gets blurred in this topic: most clinical trials of cinnamon and glycemia were conducted in people already diagnosed with type 2 diabetes, not in people with insulin resistance alone or prediabetes without full-blown disease. This is a difference we return to later in the article, because it directly matters for who these results actually apply to.

Interest in cinnamon in the context of glycemia didn't come out of nowhere. Since the 1990s, laboratory studies have indicated that certain compounds present in cinnamon — mainly procyanidin-type polyphenols — may mimic part of insulin's action at the cellular level or enhance insulin receptor activity. It has also been proposed that cinnamon may slow gastric emptying and inhibit certain digestive enzymes that break down carbohydrates, which would theoretically flatten the post-meal rise in glucose.

This mechanistic uncertainty is normal at an early stage of research into natural compounds — we've already seen a similar pattern (a promising lab mechanism, a less clear-cut clinical effect) with other interventions for insulin resistance that we describe in our knowledge base. So the key question isn't "does cinnamon do something in a test tube," but "is the effect large and reproducible enough in humans to be clinically meaningful."

The results are expressed as a standardized mean difference (SMD) rather than in clinical units like mg/dl or percent HbA1c — a way of pooling results from studies that measured the same parameters using different methods or units. An SMD of around -1.32 is, by statistical convention, a large effect, not a cosmetic one — one of the reasons the results of this meta-analysis are often cited as a strong argument in favor of cinnamon. It's worth remembering, though, that a large SMD in a meta-analysis of studies with varying quality and sample size doesn't always translate one-to-one into an equally large, predictable effect in a given patient.

The name "cinnamon" on a store shelf and in scientific studies can be misleading, because it covers at least several different species of the genus Cinnamomum. Two matter most in practice: Cinnamomum cassia (Chinese cinnamon, much cheaper and most commonly found in ordinary grocery stores) and Cinnamomum verum, also known as Ceylon or "true" cinnamon (more expensive, less commonly available, and considered a qualitatively different product).

The clinical trials included in meta-analyses, including the 2024 paper discussed above, don't always precisely report which cinnamon species they tested — and those that do differ from one another. This is a serious interpretive problem: if some trials tested cassia, some tested verum, and still others tested extracts standardized to specific active compounds, then the meta-analysis's averaged result describes the effect of "cinnamon as a category," not necessarily the effect of a specific product you can buy in a store.

The practical consequence of this heterogeneity is simple: a teaspoon of cassia cinnamon added to oatmeal and a concentrated Ceylon cinnamon extract in a capsule are, from the standpoint of active-compound dose and coumarin risk, two different things — even though both carry the same name on the label.

This distinction isn't nitpicking. Insulin resistance without diabetes is a state in which the pancreas is still largely compensating for the problem — fasting glucose is often normal or only mildly elevated, and HOMA-IR is elevated more subtly than in someone with overt diabetes. Extrapolating results from a population with advanced glycemic disturbance to a population with an early, compensated disturbance is always risky — it can both overestimate and underestimate the real benefit, since compensatory mechanisms behave differently at different stages.

Since cinnamon lowered fasting glucose in clinical trials, the logical consequence is that for someone already taking blood-sugar-lowering medications — metformin, sulfonylureas, or insulin — adding another intervention with a similar direction of effect theoretically increases the risk of an excessive drop in glycemia, i.e. hypoglycemia. Symptoms of hypoglycemia (hand tremor, cold sweats, palpitations, disorientation) can be unpleasant and, in extreme cases, dangerous, especially while driving or doing work that requires concentration.

None of the trials included in the meta-analysis discussed here reported mass cases of severe hypoglycemia, but that isn't the same as proof of full safety when combining high-dose cinnamon with hypoglycemic medications in everyday life, outside the controlled environment of a clinical trial. That's why people treating diabetes or insulin resistance pharmacologically should treat regular, high-dose cinnamon supplementation as something to discuss with their doctor, not as a neutral dietary addition that can be introduced without consultation.

Cinnamon belongs to a small group of popular "natural" glycemic interventions genuinely backed by a solid number of randomized trials, rather than just a handful of small studies or folk tradition. That sets it apart from many other, less-studied proposals. At the same time, the scale of heterogeneity in these trials — different species, doses, and durations — and the fact that the evidence primarily concerns people who already have developed type 2 diabetes, call for treating enthusiastic headlines with some caution.